Gastroenterology

April 8th 2025

Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative colitis and Crohn disease, and was less costly in ulcerative colitis, according to a real-world economic analysis from the EVOLVE study.

April 7th 2025

This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies.

April 1st 2025

Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.

March 21st 2025

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy received a second CRL as a frontline therapy for unresectable hepatocellular carcinoma (HCC).